Cargando…
Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
The anti-proliferative activities of all twenty-five targeted kinase inhibitor drugs that are in clinical use were measured in two large assay panels: (1) a panel of proliferation assays of forty-four human cancer cell lines from diverse tumour tissue origins; and (2) a panel of more than 300 kinase...
Autores principales: | Uitdehaag, Joost C. M., de Roos, Jeroen A. D. M., van Doornmalen, Antoon M., Prinsen, Martine B. W., de Man, Jos, Tanizawa, Yoshinori, Kawase, Yusuke, Yoshino, Kohichiro, Buijsman, Rogier C., Zaman, Guido J. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961306/ https://www.ncbi.nlm.nih.gov/pubmed/24651269 http://dx.doi.org/10.1371/journal.pone.0092146 |
Ejemplares similares
-
Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
por: Uitdehaag, Joost C. M., et al.
Publicado: (2015) -
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
por: Kooijman, Jeffrey J., et al.
Publicado: (2022) -
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
por: Grobben, Yvonne, et al.
Publicado: (2021) -
Pharmacological validation of TDO as a target for Parkinson’s disease
por: Perez‐Pardo, Paula, et al.
Publicado: (2021) -
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158
por: Grobben, Yvonne, et al.
Publicado: (2019)